Abstract | PURPOSE: METHODS: This was a double-blind, placebo-controlled, randomised, parallel group, uptitration study. Male and female subjects received ascending oral doses of ponesimod (n=12) or placebo (n=4) once daily for 3 days at each dose level (10-20-40-60-80-100mg). RESULTS: The most frequent adverse events were chest discomfort, headache, dizziness, dyspnoea, abdominal pain, and night sweats. Chest discomfort and dyspnoea were considered dose-limiting. A transient decrease in heart rate was observed following the first 10-mg ponesimod dose (maximum mean decrease of 9 beats per minute (bpm) (placebo: 2 bpm)). After uptitration, effects on heart rate were indistinguishable from placebo. A dose-dependent effect on pulmonary function tests was observed and reached a plateau with 60-80 mg ponesimod (maximum mean decrease from baseline of 1.24l (-30.5%) in forced expiratory volume in 1s). A plateau in mean lymphocyte count reduction of approximately 70% from baseline was reached at the 40 mg dose level. Observed effects were fully reversible within 10days after treatment discontinuation. No relevant sex differences were observed. CONCLUSIONS: At supratherapeutic doses, symptoms of chest discomfort and dyspnoea were dose-limiting. An uptitration dosing scheme is to be preferred in clinical studies in patients in order to limit effects of ponesimod on heart rate and atrioventricular (AV) conduction.
|
Authors | M Hoch, D D'Ambrosio, D Wilbraham, P Brossard, J Dingemanse |
Journal | European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences
(Eur J Pharm Sci)
Vol. 63
Pg. 147-53
(Oct 15 2014)
ISSN: 1879-0720 [Electronic] Netherlands |
PMID | 25046167
(Publication Type: Journal Article, Randomized Controlled Trial)
|
Copyright | Copyright © 2014. Published by Elsevier B.V. |
Chemical References |
- Receptors, Lysosphingolipid
- Thiazoles
- ponesimod
|
Topics |
- Adolescent
- Adult
- Aged
- Dose-Response Relationship, Drug
- Double-Blind Method
- Drug Administration Schedule
- Female
- Humans
- Male
- Middle Aged
- Receptors, Lysosphingolipid
(metabolism)
- Thiazoles
(administration & dosage, adverse effects, pharmacology)
- Young Adult
|